vs
Revvity（RVTY）与SCANSOURCE, INC.（SCSC）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是SCANSOURCE, INC.的1.0倍（$772.1M vs $766.5M），Revvity净利率更高（12.7% vs 2.2%，领先10.6%），Revvity同比增速更快（5.9% vs 2.5%），Revvity自由现金流更多（$161.8M vs $28.9M），过去两年Revvity的营收复合增速更高（9.0% vs 0.9%）
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
ScanSource是全球领先的专业技术分销商，主营销售点系统、条码扫描设备、网络安全产品、云服务及通信解决方案，面向北美、拉美、欧洲的增值经销商、服务提供商及企业客户，覆盖零售、医疗、工业、公共部门等领域。
RVTY vs SCSC — 直观对比
营收规模更大
RVTY
是对方的1.0倍
$766.5M
营收增速更快
RVTY
高出3.3%
2.5%
净利率更高
RVTY
高出10.6%
2.2%
自由现金流更多
RVTY
多$132.9M
$28.9M
两年增速更快
RVTY
近两年复合增速
0.9%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $772.1M | $766.5M |
| 净利润 | $98.4M | $16.5M |
| 毛利率 | — | 13.4% |
| 营业利润率 | 14.5% | 2.3% |
| 净利率 | 12.7% | 2.2% |
| 营收同比 | 5.9% | 2.5% |
| 净利润同比 | 3.9% | -3.3% |
| 每股收益（稀释后） | $0.86 | $0.75 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收RVTYSCSC
| Q4 25 | $772.1M | $766.5M | ||
| Q3 25 | $698.9M | $739.6M | ||
| Q2 25 | $720.3M | $812.9M | ||
| Q1 25 | $664.8M | $704.8M | ||
| Q4 24 | $729.4M | $747.5M | ||
| Q3 24 | $684.0M | $775.6M | ||
| Q2 24 | $691.7M | $746.1M | ||
| Q1 24 | $649.9M | $752.6M |
净利润RVTYSCSC
| Q4 25 | $98.4M | $16.5M | ||
| Q3 25 | $46.7M | $19.9M | ||
| Q2 25 | $53.9M | $20.1M | ||
| Q1 25 | $42.2M | $17.4M | ||
| Q4 24 | $94.6M | $17.1M | ||
| Q3 24 | $94.4M | $17.0M | ||
| Q2 24 | $55.4M | $16.1M | ||
| Q1 24 | $26.0M | $12.8M |
毛利率RVTYSCSC
| Q4 25 | — | 13.4% | ||
| Q3 25 | 53.6% | 14.5% | ||
| Q2 25 | 54.5% | 12.9% | ||
| Q1 25 | 56.5% | 14.2% | ||
| Q4 24 | — | 13.6% | ||
| Q3 24 | 56.3% | 13.1% | ||
| Q2 24 | 55.7% | 13.0% | ||
| Q1 24 | 54.6% | 12.6% |
营业利润率RVTYSCSC
| Q4 25 | 14.5% | 2.3% | ||
| Q3 25 | 11.7% | 3.5% | ||
| Q2 25 | 12.6% | 3.3% | ||
| Q1 25 | 10.9% | 3.2% | ||
| Q4 24 | 16.3% | 2.5% | ||
| Q3 24 | 14.3% | 2.3% | ||
| Q2 24 | 12.4% | 2.9% | ||
| Q1 24 | 6.8% | 2.3% |
净利率RVTYSCSC
| Q4 25 | 12.7% | 2.2% | ||
| Q3 25 | 6.7% | 2.7% | ||
| Q2 25 | 7.5% | 2.5% | ||
| Q1 25 | 6.4% | 2.5% | ||
| Q4 24 | 13.0% | 2.3% | ||
| Q3 24 | 13.8% | 2.2% | ||
| Q2 24 | 8.0% | 2.2% | ||
| Q1 24 | 4.0% | 1.7% |
每股收益（稀释后）RVTYSCSC
| Q4 25 | $0.86 | $0.75 | ||
| Q3 25 | $0.40 | $0.89 | ||
| Q2 25 | $0.46 | $0.87 | ||
| Q1 25 | $0.35 | $0.74 | ||
| Q4 24 | $0.77 | $0.70 | ||
| Q3 24 | $0.77 | $0.69 | ||
| Q2 24 | $0.45 | $0.66 | ||
| Q1 24 | $0.21 | $0.50 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $919.9M | $83.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $7.3B | $910.9M |
| 总资产 | $12.2B | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资RVTYSCSC
| Q4 25 | $919.9M | $83.5M | ||
| Q3 25 | $931.4M | $124.9M | ||
| Q2 25 | $991.8M | $126.2M | ||
| Q1 25 | $1.1B | $146.3M | ||
| Q4 24 | $1.2B | $110.5M | ||
| Q3 24 | $1.2B | $145.0M | ||
| Q2 24 | $2.0B | $185.5M | ||
| Q1 24 | $1.7B | $159.1M |
股东权益RVTYSCSC
| Q4 25 | $7.3B | $910.9M | ||
| Q3 25 | $7.4B | $914.0M | ||
| Q2 25 | $7.6B | $906.4M | ||
| Q1 25 | $7.6B | $901.7M | ||
| Q4 24 | $7.7B | $900.7M | ||
| Q3 24 | $7.9B | $920.9M | ||
| Q2 24 | $7.9B | $924.3M | ||
| Q1 24 | $7.8B | $944.1M |
总资产RVTYSCSC
| Q4 25 | $12.2B | $1.7B | ||
| Q3 25 | $12.1B | $1.7B | ||
| Q2 25 | $12.4B | $1.8B | ||
| Q1 25 | $12.4B | $1.7B | ||
| Q4 24 | $12.4B | $1.7B | ||
| Q3 24 | $12.8B | $1.8B | ||
| Q2 24 | $13.4B | $1.8B | ||
| Q1 24 | $13.4B | $1.8B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $182.0M | $30.8M |
| 自由现金流经营现金流 - 资本支出 | $161.8M | $28.9M |
| 自由现金流率自由现金流/营收 | 21.0% | 3.8% |
| 资本支出强度资本支出/营收 | 2.6% | 0.3% |
| 现金转化率经营现金流/净利润 | 1.85× | 1.87× |
| 过去12个月自由现金流最近4个季度 | $509.4M | — |
8季度趋势，按日历期对齐
经营现金流RVTYSCSC
| Q4 25 | $182.0M | $30.8M | ||
| Q3 25 | $138.5M | $23.2M | ||
| Q2 25 | $134.3M | — | ||
| Q1 25 | $128.2M | $66.1M | ||
| Q4 24 | $174.2M | $-6.2M | ||
| Q3 24 | $147.9M | $44.8M | ||
| Q2 24 | $158.6M | — | ||
| Q1 24 | $147.6M | $160.2M |
自由现金流RVTYSCSC
| Q4 25 | $161.8M | $28.9M | ||
| Q3 25 | $120.0M | $20.8M | ||
| Q2 25 | $115.5M | — | ||
| Q1 25 | $112.2M | $64.6M | ||
| Q4 24 | $149.8M | $-8.2M | ||
| Q3 24 | $125.6M | $42.5M | ||
| Q2 24 | $136.6M | — | ||
| Q1 24 | $129.7M | $157.7M |
自由现金流率RVTYSCSC
| Q4 25 | 21.0% | 3.8% | ||
| Q3 25 | 17.2% | 2.8% | ||
| Q2 25 | 16.0% | — | ||
| Q1 25 | 16.9% | 9.2% | ||
| Q4 24 | 20.5% | -1.1% | ||
| Q3 24 | 18.4% | 5.5% | ||
| Q2 24 | 19.7% | — | ||
| Q1 24 | 20.0% | 21.0% |
资本支出强度RVTYSCSC
| Q4 25 | 2.6% | 0.3% | ||
| Q3 25 | 2.6% | 0.3% | ||
| Q2 25 | 2.6% | 0.3% | ||
| Q1 25 | 2.4% | 0.2% | ||
| Q4 24 | 3.4% | 0.3% | ||
| Q3 24 | 3.3% | 0.3% | ||
| Q2 24 | 3.2% | 0.2% | ||
| Q1 24 | 2.7% | 0.3% |
现金转化率RVTYSCSC
| Q4 25 | 1.85× | 1.87× | ||
| Q3 25 | 2.97× | 1.17× | ||
| Q2 25 | 2.49× | — | ||
| Q1 25 | 3.03× | 3.79× | ||
| Q4 24 | 1.84× | -0.36× | ||
| Q3 24 | 1.57× | 2.64× | ||
| Q2 24 | 2.87× | — | ||
| Q1 24 | 5.67× | 12.51× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
SCSC
| Products And Services | $723.4M | 94% |
| Intelisys Advisory | $25.0M | 3% |
| Recurring Revenue | $18.2M | 2% |
